ORLANDO, Fla.--(BUSINESS WIRE)--Amgen (NASDAQ: AMGN) today announced that after 53/55 weeks of treatment with Aranesp® (darbepoetin alfa) administered every three weeks, 74 percent of anemic patients with low- or intermediate-risk myelodysplastic syndromes who had not previously received an erythropoiesis-stimulating agent (ESA) had an erythroid response, with 59 percent classified as major response. These final data were presented at the American Society of Hematology (ASH) 48th Annual Meeting in Orlando, Fla. (Abstract # 2671)
